Advances in our understanding of the molecular basis of cancer have shown that biomarkers can help guide therapy in a growing number of cancer types and that targeted therapies are becoming increasingly integral to cancer management. However, how to interpret the rapidly expanding wealth of data on cancer genomics and ensure that the best evidence is effectively translated into an optimal individualised therapeutic strategy, remains a challenge. Caris Target Now™ is a well-established, evidence-based molecular profiling service provided by Caris Life Sciences (Basel, Switzerland). Caris Target Now utilises the latest diagnostic molecular assay technologies to determine the unique biomarkers of a patient's tumour. This is combined with an extensive review of the published clinical evidence to correlate predictive biomarkers with drug response, in order to reveal the potential benefit (or lack of benefit) of specific therapeutic agents. By this process, Target Now provides tumour-specific information that can be used to help physicians personalise cancer therapy for their patients.
1
Most cancer therapies gain approval despite typical response rates of around only one-third of patients. 2 Thus, a significant proportion of cancer patients receive treatment of limited clinical benefit. Better targeted clinical decision-making early in the disease course would improve outcomes for patients. More comprehensive and earlier use of molecular profiling could result in more patients receiving effective therapy at a stage where benefits may be optimal rather than after one or more lines of failed treatment, an especially important consideration in aggressive cancers for which the time window for effective intervention may be limited. It may also mean that patients with rare cancers, which have a limited evidence-base and few treatment options, may be able to benefit from existing targeted therapies.
A more personalised approach to patient care, with targeted treatment directed by the molecular profile of the tumour rather than a 'one-size-fits-all' strategy, would also lead to more effective allocation of limited financial resources. and PTEN status, more non-responders to EGFR inhibitor therapy could be excluded from treatment (see Figure 2 ). 12 However, it is unlikely that large-scale randomised controlled trials to support targeted therapy outside of initially approved indications will be conducted, due to the difficulty in recruiting sufficient numbers of patients, as well as the often limited patent protection after lengthy secondary development.
Advances in our understanding of the molecular basis of cancer have
shown that biomarkers can help guide therapy in a growing number of cancer types and targeted therapeutics are becoming increasingly integral to cancer management. However, how to interpret the rapidly expanding wealth of data on cancer genomics and ensure that the best evidence is effectively translated into an optimal individualised therapeutic strategy remains a challenge. One potential approach that is gaining momentum is the use of evidence-driven molecular profiling services to guide targeted therapy choices.
Target Now™
Caris Target Now is a well-established evidence-based molecular profiling service provided by Caris Life Sciences (Basel, Switzerland).
Caris Target Now utilises the latest diagnostic molecular assay technologies to determine the unique biomarkers of a patient's tumour. This is combined with an extensive review of the clinical evidence base to correlate predictive biomarkers with drug response, in order to reveal the benefit (or lack of benefit) of specific therapeutic agents. By this process, Target Now provides tumour-specific information that can be used to help physicians personalise cancer therapy for their patients.
Target Now is suitable for any patient with a solid tumour diagnosis.
The stage in the clinical pathway where the analysis is performed will depend on the individual patient. However, it is most frequently used for patients with advanced disease receiving standard of care treatment where multiple options are available but the optimal therapeutic strategy is unclear, and patients for whom standard of care options have been exhausted or are not an option, for example due to co-morbidities.
In addition, patients with highly aggressive or rare tumours, advanced disease or a good performance status and a wish to continue with further treatment options may also be appropriate candidates. Pathology and molecular genetics play a critical role in Target Now.
Board-certified, experienced oncologic pathologists oversee molecular testing from the time the test is ordered to the generation of a final Target Now report.
The Target Two distinct profiling options are offered as part of Target Now (see Table 1 ). Target 
The Bisgrove Study
The Bisgrove study was the first clinical trial to assess the use of molecular profiling of tumours to identify treatment targets in patients with refractory cancers. 22 In 
Other Studies
Other data also suggest molecular profiling may have a positive effect on treatment outcomes. In a single-centre pilot study of patients with advanced refractory solid tumours, six of nine patients who received treatment guided by molecular profiling (Target Now) showed a clinical response. 23 In another pilot study in patients with adenoid cystic carcinoma, four of six patients showed at least a partial response over six months to molecular profile-directed therapy, including one patient who initially had multiple lung, liver and bone metastases with no evidence of disease for over 15 months. 24 Similarly, in a retrospective study conducted at the University of 
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To 
Conclusions
Identifying clinically relevant and patient-specific biomarkers can help guide more effective and targeted treatment. As treatment costs in oncology continue to rise, the need for smarter, more accurate targeting of treatments will become increasingly imperative. As part of this, there is a requirement for evidence-based strategies that help translate the growing body of complex biomarker data into clinically relevant treatment recommendations. Caris Target Now, a molecular profiling service that combines state-of-the-art biomarker analysis with systematic evidence-based literature review to offer a rational, personalised therapeutic strategy, is one such approach with the potential to improve clinical outcomes for appropriate patients. n 
